A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2‐related cancers. A test to identify additional HRR‐deficient tumors will help to extend their use in new indications. We evaluated the activity o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :EMBO Mol Med
Главные авторы: Castroviejo‐Bermejo, Marta, Cruz, Cristina, Llop‐Guevara, Alba, Gutiérrez‐Enríquez, Sara, Ducy, Mandy, Ibrahim, Yasir Hussein, Gris‐Oliver, Albert, Pellegrino, Benedetta, Bruna, Alejandra, Guzmán, Marta, Rodríguez, Olga, Grueso, Judit, Bonache, Sandra, Moles‐Fernández, Alejandro, Villacampa, Guillermo, Viaplana, Cristina, Gómez, Patricia, Vidal, Marc, Peg, Vicente, Serres‐Créixams, Xavier, Dellaire, Graham, Simard, Jacques, Nuciforo, Paolo, Rubio, Isabel T, Dientsmann, Rodrigo, Barrett, J Carl, Caldas, Carlos, Baselga, José, Saura, Cristina, Cortés, Javier, Déas, Olivier, Jonkers, Jos, Masson, Jean‐Yves, Cairo, Stefano, Judde, Jean‐Gabriel, O'Connor, Mark J, Díez, Orland, Balmaña, Judith, Serra, Violeta
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6284440/
https://ncbi.nlm.nih.gov/pubmed/30377213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201809172
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы